On May 12, President Trump issued an Executive Order that directed pharmaceutical manufacturers to reduce US drug prices to align with those paid in economically comparable countries, a concept known as international reference pricing or Most-Favored Nation (MFN). In the months since, federal health agencies have published policy releases referencing the Executive Order, and the White House has continued to meet with manufacturers to evaluate potential MFN options.  

On August 20 at 9:30 AM ET / 2:30 PM GMT, Avalere Health Advisory experts will break down key facets of MFN pricing proposals, including: 

• Current State of Play: The latest thinking on evolving MFN pricing proposals and implementation steps to date.  

• Future Directions: Areas for future policy action, including the enforcement of MFN prices and the creation of direct-to-consumer models.  

• Policy Interaction: How MFN approaches could intersect with other drug pricing initiatives, including the Inflation Reduction Act, pharmacy benefit manager reform, and state upper payment limits. 

• Strategy Considerations: How manufacturers can tailor their business strategies to adapt and mitigate, including through changes to pricing strategy, distribution approach, and launch sequence. 

Panelists:

• Mina Allo, Managing Director, Market Access
• Michael Ciarametero, Managing Director, Policy
• Caroline Solon, Senior Director, Market Access
• Megan West, Managing Director, Policy